rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

VivoSim Labs, Inc.

VIVS · Nasdaq

Health CareBiotechnologyNot moving yet

VIVS stood above a rising 150-day average in 3 of the last 52 weekly readings, and has been out of that trend for the last 37 weeks. It is 81.8% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 37
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$5,604
Insider sales, 12 months
$7,316
Officials’ trades on record
0
Institutions holding
23 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 3 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$6,851$0$5,139Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months1
Buyers · sellers1 · 1
WhoDidSharesTraded
Tony Serge LialinChief Commercial Officerbought10,000at $0.280431 Aug 2026filed 1 Sep 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders23+0 on the quarter
New · exited3 · 3
Reported value$91K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202625,976$28K-10,874−29.5%
RENAISSANCE TECHNOLOGIES LLCnew · filed 13 Aug 202618,500$20K+18,500
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 202615,371$16K00.0%
BlackRock, Inc.unchanged · filed 7 Aug 202611,817$13K00.0%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 20267,003$7,49300.0%
Tower Research Capital LLC (TRC)added · filed 11 Aug 20265,249$5,616+2,941+127.4%
SBI Securities Co., Ltd.unchanged · filed 23 Jul 2026221$23600.0%
Larson Financial Group LLCunchanged · filed 14 Aug 2026166$17800.0%
ALBION FINANCIAL GROUPunchanged · filed 22 Jul 2026159$17100.0%
WELLS FARGO & COMPANYunchanged · filed 14 Aug 2026111$11900.0%
31 Mar 2023 – 30 Jun 2026
202632Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Tony Serge Lialin Company insiderChief Commercial Officer · last 31 Aug 20261 · 0
Adam K. Stern Company insiderDirector · last 27 Jan 20260 · 0
Alison Tjosvold Milhous Company insiderDirector · last 27 Jan 20260 · 0
David Gobel Company insiderDirector · last 27 Jan 20260 · 3
Douglas Jay Cohen Company insiderDirector · last 27 Jan 20261 · 0
Keith Murphy Company insiderEXECUTIVE CHAIRMAN · last 27 Jan 20263 · 10
Amar Akhtar Sethi Company insiderChief Scientific Officer · last 25 Nov 20250 · 0
Vaidehi Joshi Company insiderDirector · last 7 Aug 20240 · 0
Jeffrey N. Miner Company insiderChief Scientific Officer · last 31 Aug 20220 · 0
Thomas E. Jurgensen Company insiderGeneral Counsel & Secretary · last 31 Aug 20220 · 0
Chris Heberlig Company insiderPresident and CFO · last 15 Sep 20200 · 0
Craig Kussman Company insiderChief Financial Officer · last 18 Aug 20200 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2026 · to 31 Mar 2026100%
Share count trendFY 2026 · to 10 Jul 202620.7%
Cash and equivalentsFY 2026 · to 31 Mar 2026$5.0M
Free cash flowFY 2026 · to 31 Mar 2026−$10.8M

Analyst forecasts

No analyst forecasts yet.